Lonza Completes Acquisition of Biologics Site from Roche

Lonza, the healthcare development and manufacturing organization, has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for $1.2 billion. The Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the US, the world’s largest pharmaceutical market. It also creates a significant West Coast commercial manufacturing presence close to San Francisco’s pharma and biotech hub, complementing Lonza’s existing East Coast manufacturing site in Portsmouth, New Hampshire, as well as its international network across Europe and Asia Pacific. With a total bioreactor capacity of around 330,000 liters, the Vacaville site is one of the largest biologics manufacturing facilities in the world.

Read the full article: Lonza Completes Acquisition of Biologics Site from Roche //

Source: https://www.contractpharma.com/live-from-shows/cphi-milan/2024-10-01/lonza-completes-acquisition-of-biologics-site-from-roche

Scroll to Top